Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
31 March 2017

Oryzon Raises €18 Million through a Private Placement with US and European Investors

20 March 2017

Oryzon to Present at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum

15 March 2017

ORYZON to Present at the 11th Annual BIO-Europe Spring International Partnering Conference

27 February 2017

ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017

24 February 2017

ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016

20 February 2017

ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA

6 February 2017

Oryzon Genomics to Present at the 19th Annual BIO CEO & Investor Conference 2017

3 February 2017

Oryzon received Best Business Practices Award for Innovation

30 January 2017

ORYZON to outline development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Diseases at Keystone Symposia on Epigenetics and Human Disease

25 January 2017

ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • Current page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel